Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
WJ Gradishar, MS Moran, J Abraham… - Journal of the National …, 2024 - jnccn.org
Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis
LM Spring, G Fell, A Arfe, C Sharma, R Greenup… - Clinical cancer …, 2020 - AACR
Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
Breast cancer
N Harbeck, F Penault-Llorca… - Nature reviews …, 2019 - mayoclinic.elsevierpure.com
Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
Breast cancer treatment: a review
AG Waks, EP Winer - Jama, 2019 - jamanetwork.com
Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies
Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and
ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to …
ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to …
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However,
experimental studies in mice also suggest that chemotherapy has pro-metastatic effects …
experimental studies in mice also suggest that chemotherapy has pro-metastatic effects …